ARTICLE | Clinical News
R7128: Additional Phase I data
September 15, 2008 7:00 AM UTC
Twenty-five patients with HCV genotype 2 or 3 who failed prior Pegasys peginterferon alfa-2a plus Copegus ribavirin therapy were enrolled in the fourth cohort of a single-blind, placebo-controlled, ...